Bismuth213QualityChecker

Bismuth-213

radiopharmaceuticals QC URS & FS input.csv output.json alpha therapy SPECT radiochemical purity
Open selection

Utility description: Bismuth-213

Bismuth-213 Quality Checker — Bismuth-213 for targeted alpha therapy

ℹ️  Utility checks critical parameters of bismuth-213:
    • Radionuclidic purity (≥99.9%)
    • Actinium-225 breakthrough (≤0.01%) — CRITICAL! (Generator leakage)
    • Radiochemical purity (≥95%)
    • Free bismuth (≤5%) — kidney accumulation risk
    • pH (4.0–6.0), endotoxins, sterility

⚠️  CRITICAL: Actinium-225 breakthrough >0.01% → uncontrolled alpha emission in healthy tissues!
    Free bismuth >5% → kidney and liver toxicity!
    Short half-life (45.6 min) requires rapid quality control!

Usage:
  Bismuth213QualityChecker.exe                            → demo mode (console output)
  Bismuth213QualityChecker.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Ac225BreakthroughPercent,RadiochemicalPurityPercent,FreeBismuthPercent,pH,EndotoxinsEU,SterilityTest,ProductType

Example (sterility: 0=sterile, 1=contaminated):
  BI213-PSMA-2026-001,300.0,99.95,0.005,98.0,1.5,5.0,40.0,0,PSMA

Supported product types:
• PSMA — therapy for prostate cancer
• DOTATATE — therapy for neuroendocrine tumors
• ANTIBODY — targeted alpha therapy with monoclonal antibodies
• FREECHLORIDE — precursor bismuth-213 chloride

— WHY IS THIS NEEDED?
Bismuth-213 is a potent alpha-emitter obtained from an Ac-225/Bi-213 generator:
• 45.6-minute half-life — requires rapid synthesis and administration ("just-in-time" therapy)
• Alpha radiation (8.4 MeV) — high LET, effectively destroys resistant cells
• Generator system — allows isotope production in the clinic without a cyclotron
• Used in leukemias, glioblastomas, and metastatic cancer

⚠️  CRITICAL:
• Radionuclidic purity ≥99.9% — absence of other radioactive impurities
• Actinium-225 breakthrough ≤0.01% — CRITICAL! Ac-225 (T½=10 days) has a long decay chain. If it enters the drug, it will circulate in the blood and irradiate bone marrow and kidneys with long-lived daughters.
• Radiochemical purity ≥95% — free Bi-213 rapidly accumulates in kidneys, causing nephrotoxicity.
• Free bismuth ≤5% — controls chelation efficiency (DOTA, CHX-A''-DTPA).
• pH 4.0–6.0 — optimal for stability of Bi-213 complexes and preventing hydrolysis.
• Endotoxins ≤175 EU/vial — critical for IV administration!
• Sterility — MANDATORY for all parenteral forms!

Key features:
• Check of parent breakthrough (Ac-225) — main safety parameter for generator systems
• Control of free bismuth to assess nephrotoxicity risk
• Support for different product types (PSMA, peptides, antibodies)
• Consideration of short half-life in activity calculations
• Critical warnings about long-term irradiation from Ac-225

Critical parameters:
• Radionuclidic purity: ≥99.9%
• Actinium-225 breakthrough: ≤0.01% (CRITICAL!)
• Radiochemical purity: ≥95.0%
• Free bismuth: ≤5.0%
• pH: 4.0–6.0
• Endotoxins: ≤175 EU/vial
• Sterility: no microbial growth

💡 Usage tips:
1. Ac-225 breakthrough controlled by gamma spectrometry (peaks of Ac-225 daughters, e.g., Fr-221 or Bi-213 in equilibrium, accounting for time).
2. Radiochemical purity determined by TLC or HPLC.
3. Due to short T½ (45.6 min), all measurements must be performed rapidly, with mandatory decay correction to calibration time.
4. Bi-213 chelation often uses macrocycles (DOTA) or acyclic chelators (CHX-A''-DTPA), requiring different pH conditions.
5. If Ac-225 breakthrough >0.01% detected — eluate should not be used for labeling without additional purification.

⚠️ Note: Bismuth-213 is the "emergency response" of alpha therapy. Its main advantage is the lack of long-lived daughters from Bi-213 itself (decays to stable Bi-209 via short-lived isotopes). However, the risk of contamination with parent Ac-225 makes control of generator breakthrough an absolute priority.

input.csv

BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Ac225BreakthroughPercent,RadiochemicalPurityPercent,FreeBismuthPercent,pH,EndotoxinsEU,SterilityTest,ProductType
BI213-DEMO-001,300.0,99.95,0.005,98.0,1.5,5.0,40.0,0,PSMA
BI213-FAIL-002,280.0,99.0,0.05,90.0,8.0,3.5,100.0,0,DOTATATE

URS & FS — User Requirements and Functional Specification

1. Scope

This document defines requirements and functional behaviour for Bismuth213QualityChecker used to control: Bismuth-213. The utility is intended for QC use and applies deterministic rules, not machine learning.

2. Execution modes

  • Bismuth213QualityChecker.exe — demo mode or help output.
  • Bismuth213QualityChecker.exe input.csv output.json — process user data and write result.

3. Key source-derived controls

  • Bismuth-213 Quality Checker — Bismuth-213 for targeted alpha therapy
  • ℹ️ Utility checks critical parameters of bismuth-213:
  • • Radionuclidic purity (≥99.9%)
  • • Actinium-225 breakthrough (≤0.01%) — CRITICAL! (Generator leakage)
  • • Radiochemical purity (≥95%)
  • • Free bismuth (≤5%) — kidney accumulation risk
  • • pH (4.0–6.0), endotoxins, sterility
  • ⚠️ CRITICAL: Actinium-225 breakthrough >0.01% → uncontrolled alpha emission in healthy tissues!
  • BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Ac225BreakthroughPercent,RadiochemicalPurityPercent,FreeBismuthPercent,pH,EndotoxinsEU,SterilityTest,ProductType
  • Example (sterility: 0=sterile, 1=contaminated):
  • • ANTIBODY — targeted alpha therapy with monoclonal antibodies
  • Bismuth-213 is a potent alpha-emitter obtained from an Ac-225/Bi-213 generator:
  • • Alpha radiation (8.4 MeV) — high LET, effectively destroys resistant cells
  • ⚠️ CRITICAL:
  • • Radionuclidic purity ≥99.9% — absence of other radioactive impurities
  • • Actinium-225 breakthrough ≤0.01% — CRITICAL! Ac-225 (T½=10 days) has a long decay chain. If it enters the drug, it will circulate in the blood and irradiate bone marrow and kidneys with long-lived daughters.
  • • Radiochemical purity ≥95% — free Bi-213 rapidly accumulates in kidneys, causing nephrotoxicity.
  • • Free bismuth ≤5% — controls chelation efficiency (DOTA, CHX-A''-DTPA).
  • • pH 4.0–6.0 — optimal for stability of Bi-213 complexes and preventing hydrolysis.
  • • Endotoxins ≤175 EU/vial — critical for IV administration!

4. URS — user requirements

IDRequirementCriticalityAcceptance criterion
URS-001The utility shall accept input.csv with the exact headers defined in the data contract.HighThe file is processed without manual header changes.
URS-002The utility shall validate mandatory fields, data types, ranges, units, and critical pharmaceutical/radiochemical limits.HighEach row receives PASS/WARNING/FAIL status.
URS-003The utility shall detect critical deviations related to radionuclidic/radiochemical purity, impurities, free radionuclide, pH, endotoxins and sterility where such fields are present.HighA critical deviation produces FAIL or an explicit critical finding.
URS-004The utility shall generate output.json with machine-readable results, source values, warnings and failures.HighJSON is suitable for LIMS/ELN/MES integration and QA/QC review.
URS-005The utility shall not use machine learning to decide conformance.MediumThe decision is based on explicit rules and thresholds.
URS-006The utility shall preserve traceability between batch number, input values, applied rules and final status.HighThe output contains batch identifier and checked parameters.
URS-007The documentation shall support IQ/OQ preparation and inspection discussion with FDA/EMA/Roszdravnadzor or local regulator.MediumURS/FS and test scenarios are supplied with the utility.

5. input.csv contract

#FieldTypeSamplePurpose
1BatchNumberstringBI213-DEMO-001Batch or lot identifier.
2ActivityMBqdecimal300.0Activity of the radiopharmaceutical material or finished product.
3RadionuclidicPurityPercentstring99.95Radionuclidic purity; critical radiation safety attribute.
4Ac225BreakthroughPercentdecimal0.005Controlled impurity; used in PASS/WARNING/FAIL decision logic.
5RadiochemicalPurityPercentstring98.0Radiochemical purity; verifies radionuclide binding and target chemical form.
6FreeBismuthPercentdecimal1.5Free radionuclide/ion; critical due to non-target uptake and toxicity.
7pHdecimal5.0Solution pH; stability and administration compatibility parameter.
8EndotoxinsEUdecimal40.0Bacterial endotoxins; critical criterion for parenteral administration.
9SterilityTestflag 0/10Sterility test result; 0 usually means no contamination.
10ProductTypestringPSMAProduct/radiopharmaceutical type; affects control interpretation.
BatchNumber,ActivityMBq,RadionuclidicPurityPercent,Ac225BreakthroughPercent,RadiochemicalPurityPercent,FreeBismuthPercent,pH,EndotoxinsEU,SterilityTest,ProductType
BI213-DEMO-001,300.0,99.95,0.005,98.0,1.5,5.0,40.0,0,PSMA
BI213-FAIL-002,280.0,99.0,0.05,90.0,8.0,3.5,100.0,0,DOTATATE

6. FS — functional specification

IDFunctionImplementation
FS-001CSV importRead input.csv in UTF-8/CSV-compatible format; validate header and expected columns.
FS-002Schema validationValidate mandatory fields and column count; report unknown or missing key fields.
FS-003Type conversionConvert numeric, flag and text values; record invalid format as row-level error.
FS-004Rule engineApply domain rules for Bismuth-213, including critical limits from the utility description.
FS-005Status aggregationGenerate final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance.
FS-006JSON exportWrite output.json with check details, source values, warnings and critical findings.
FS-007Audit supportKeep result structure suitable for review, deviation investigation and IQ/OQ preparation.

7. output.json example

{
  "utilityId": "bismuth213-quality-checker",
  "api": "Bismuth-213",
  "overallStatus": "PASS|WARNING|FAIL",
  "sourceFile": "input.csv",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "BI213-DEMO-001",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "ActivityMBq",
      "value": "300.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "RadionuclidicPurityPercent",
      "value": "99.95",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Ac225BreakthroughPercent",
      "value": "0.005",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "RadiochemicalPurityPercent",
      "value": "98.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "FreeBismuthPercent",
      "value": "1.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "pH",
      "value": "5.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "EndotoxinsEU",
      "value": "40.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    }
  ],
  "criticalFindings": []
}

8. OQ/PQ test scenarios

IDScenarioExpected result
OQ-001Valid sample rowPASS or acceptable WARNING according to rules.
OQ-002Mandatory column is missingSchema error or FAIL.
OQ-003Non-numeric value in numeric fieldType conversion error.
OQ-004Critical parameter outside limitFAIL and critical finding.
PQ-001User real batch/lotApproved review result with input.csv and output.json retained.

9. QA/QC and change control

  • Do not rename columns without validator update.
  • Store input.csv, output.json, executable version and checksum.
  • Before production use perform IQ/OQ/PQ or equivalent CSV/CSA verification.
  • Critical radiopharmaceutical limits must be checked against the approved specification and local SOPs.

Included in packages

Andrology QC Suite

QC package for andrology: androgens, erectile-dysfunction medicines, BPH/prostate products, fertility and related hormonal checks.

Open

Endocrinology QC Suite

QC package for endocrinology: thyroid, pituitary/peptide hormones, corticosteroids, sex hormones and selected metabolic medicines.

Open

Gastroenterology QC Suite

QC package for gastroenterology: PPIs, antiemetics, prokinetics, IBD medicines, laxatives, enzymes and GI anti-infectives.

Open

Neurology QC Suite

QC package for neurology and neuropsychiatry: antiepileptics, antiparkinsonian medicines, antidepressants, antipsychotics, analgesics and neurological diagnostic radiopharmaceuticals.

Open

PetRad2: advanced radiopharmaceutical QC package

A curated set of new utilities for radionuclide control, targeted alpha therapy, specific activity, radiolysis stability and preliminary dosimetry calculations.

Open

Radiology QC Suite

QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.

Open

RPH isotope family: alpha-emitting therapy

Ac-225, Ra-223, At-211, Bi-213 and Th-227: targeted alpha therapy and daughter/recoil control.

Open

RPH organ/system: bone and musculoskeletal

Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.

Open

RPH organ/system: brain and CNS

Brain perfusion, dopamine transporter, amyloid/tau, receptor imaging and neurological SPECT/PET.

Open

RPH organ/system: endocrine, thyroid and NET

Radioiodine, thyroid/parathyroid, somatostatin receptor, MIBG and neuroendocrine workflows.

Open

RPH organ/system: hepatobiliary and GI

HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.

Open

RPH organ/system: oncology and theranostics

Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.

Open

RPH organ/system: renal and urinary

Renography, GFR/ERPF, renal uptake, DMSA/MAG3/DTPA and bladder-related workflows.

Open

RPH use case: radionuclide therapy and theranostics

Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.

Open

RPH workflow: generators and isotope purity

Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.

Open

RPH workflow: product release QC

Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.

Open

RPH workflow: stability, storage, decay and waste

Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.

Open

RPH workflow: synthesis, labelling and kit reconstitution

Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.

Open

RPH: combined radiopharmaceutical QC package

RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.

Open

Urology QC Suite

QC package for urology: BPH, urolithiasis, overactive bladder, urinary-tract infection medicines and supporting antimicrobial QC checks.

Open